Jade Biosciences Inc Dossier
Qualitative Analysis
Business overview
Jade Biosciences, Inc. (Nasdaq: JBIO) is a clinical-stage biotechnology company dedicated to developing potentially best-in-class biologic therapies for patients living with severe autoimmune and inflammatory diseases. The company was launched in 2024 around a kidney-disease and immunology pipeline engineered by Paragon Therapeutics. Jade transitioned to the public markets in April 2025 through a reverse merger with Aerovate Therapeutics, Inc.. Its lead product candidate, JADE101 (formerly JADE-001), is a monoclonal antibody targeting the cytokine A PRoliferation Inducing Ligand (APRIL), which is currently in clinical development for the treatment of immunoglobulin A nephropathy (IgAN). The company's pipeline also includes JADE201, a half-life extended afucosylated anti-BAFF-R monoclonal antibody, and JADE301, targeting an undisclosed pathway.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the lead anti-APRIL monoclonal antibody candidate, JADE101, through Phase 1 healthy volunteer testing and initiating a Phase 2 clinical trial in patients with IgA nephropathy (IgAN).
Expected impact: Aims to establish clinical proof-of-concept, reduce IgA levels, lower proteinuria, and preserve long-term kidney function in IgAN patients.
Advancing JADE201, a half-life extended, afucosylated monoclonal antibody targeting BAFF-R, into its first-in-human clinical trial.
Expected impact: Aims to validate safety, tolerability, and pharmacodynamics (including B-cell depletion) for systemic autoimmune diseases.
Nomination and IND-enabling preclinical development of JADE301, an undisclosed antibody program.
Expected impact: Expands and diversifies the company's clinical-stage autoimmune pipeline.
Strengthening the executive clinical and scientific leadership team to support late-stage clinical development and regulatory strategy.
Expected impact: Appointed Edward R. Conner, M.D. as Chief Medical Officer and elevated Andrew King, M.D., Ph.D. to President of Research & Development to drive clinical execution and regulatory interactions.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
A reverse merger transaction that allowed private Jade Biosciences to transition into a publicly traded company on the Nasdaq Capital Market under the ticker symbol 'JBIO'. The transaction was accompanied by a concurrent private placement of approximately $300 million to fund the development of Jade's autoimmune pipeline.
Financial impact: The combined company operates under the name Jade Biosciences, Inc. and secured approximately $300 million in gross proceeds (including the conversion of $95 million in convertible notes) to fund operations.
Strategic Partnerships
Jade Biosciences was launched based on assets discovered and engineered by Paragon Therapeutics. Under the agreement, Jade holds an exclusive license for JADE101 and exclusive options to license JADE201 and JADE301 (formerly JADE-003).
Terms: Terms include licensing fees, option exercise fees, and potential future milestone and royalty payments as programs progress.